Case Reports in Oncology (Mar 2020)

Outcome of Pregnancy in the Era of PEGylated Interferon-α2a in Females with Chronic Myeloid Leukemia: An Experience from Qatar

  • Mohammad Abu-Tineh,
  • Nancy Kassem,
  • Mohammad Abdul-Jaber Abdulla,
  • Omar Mohammad Ismail,
  • Khaldun Obeidat,
  • Rola Ghasoub,
  • Mohamed A. Yassin

DOI
https://doi.org/10.1159/000506590
Journal volume & issue
Vol. 13, no. 1
pp. 291 – 294

Abstract

Read online

Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative neoplasm characterized by increased proliferation of the granulocytic cell line without loss of its capacity to differentiate. It accounts for 20% of all adults affected by leukemia. Tyrosine kinase inhibitors revolutionized the treatment for CML and improved quality of life. Fertility is an important issue for both males and females. Here, we report our experience with a pregnant female with CML, and shed light on safety and efficacy of PEGylated interferon-αa in pregnant women with CML and its outcome.

Keywords